Citations 1
Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus: results from the COVAD study
Naveen, R, Nikiphorou, Elena , Joshi, Mrudula , Sen, Parikshit , Lindblom, Julius , Agarwal, Vishwesh , Tan, Ai Lyn , Salim, Babur , Ziadé, Nelly , Velikova, Tsvetelina , Gracia‐Ramos, Abraham Edgar , Kuwana, Masataka , Chinoy, Hector , Tehozol, Erick Adrian Zamora , Torre, Ignacio García-De La, Group, COVAD Study, Singh, Yogesh Preet , Ranjan, Rajiv , Pandya, Sapan C , Sharma, Aman , Manoj, Manesh , Patro, Pradeepta Sekhar , Ajmani, Sajal , Chowdhury, Abhra Chandra , Shenoy, Padnamabha, Bommakanti, Keerthi Talari, Shukla, Anuj , Pandey, Arun Kumar R, Kardeş, Sinan , Kim, Minchul , Pauling, John D , Wincup, Chris , Sambataro, Gianluca , Atzeni, Fabiola , Parisi, Simone , Bocci, Elena Bartoloni, Sainaghi, Pier Paolo , Orsolini, Giovanni , Angelis, Rossella De , Danielli, Maria Giovanna, Milchert, Marcin , Serrano, Jorge Rojas, Torre, Ignacio García-De La, Loarce‐Martos, Jesus , Prieto‐González, Sergio , Kuwana, Masataka, Nakashima, Ran , Sato, Shinji , Kimura, Naoki , Kaneko, Yuko , Tomaras, Stylianos, Aharonov, Or, Maurier, F. , Meyer, Alain , Nagy‐Vincze, Melinda , Limaye, Vidya, Needham, Merrilee , Srivastav, Nilesh , Hudson, Marie, Landon‐Cardinal, Océane , Shaharir, Syahrul Sazliyana , Zuleta, Wilmer Gerardo Rojas, Silva, José António Pereira, Gupta, Latika, Agarwal, Vikas , Parodis, Ioannis , Ravichandran, Naveen , Danieli, Maria Giovanna , Gupta, Latika , Naveen, R , Lilleker, James B , Tan, Ai Lyn , Ziade, Nelly , Gracia-Ramos, Abraham Edgar , Kuwana, Masataka , Day, Jessica , Distler, Oliver , Chinoy, Hector , Gupta, Latika , Parodis, Ioannis , Milchert, Marcin , Agarwal, Vikas , Joshi, Mrudula , Agarwal, Vishwesh , Salim, Babur , Velikova, Tsvetelina , Pauling, John D , Wincup, Chris , Zamora Tehozol, Erick Adrian , Sen, Parikshit , De Angelis, Rossella , Singh, Yogesh Preet , Day, Jessica , Makol, Ashima , Distler, Oliver , Traboco, Lisa S , Wibowo, Suryo Anggoro Kusumo , Rojas Serrano, Jorge , Torre, Ignacio García-De La, Group, COVAD Study, Barman, Bhupen , Jain, Avinash , Pilania, Rakesh Kumar , Gupta, Vikas , Kavadichanda, Chengappa G. , Phatak, Sanat B. , Goswami, Rudra P , Mathew, Ashish Jacob , Asranna, Ajay , Chandwar, Kunal , Cansu, Döndü Üsküdar , Chatterjee, Tulika , Cavagna, Lorenzo , Papa, Nicoletta Del , Govoni, Marcello , Bocci, Elena Bartoloni, Sebastiani, Gian Domenico , Fusaro, Enrico , Sebastiani, Marco , Quartuccio, Luca , Franceschini, Franco , Venerito, Vincenzo , Serrano, Jorge Rojas, Torre, Ignacio García-De La, Gil‐Vila, Albert , Gonzalez, Raquel Aranega, Kuwana, Masataka, Yoshida, Akira, Knitza, Johannes , Tomaras, Stylianos , Gromova, Margarita Aleksandrovna , Gheita, Tamer A. , Hmamouchi, Ihsane , Hoff, Leonardo Santos , Giannini, Margherita , Campagne, Julien , Langguth, Daman , Limaye, Vidya , Silva, José António Pereira, Fonseca, João Eurico , Zimba, Olena , Aggarwal, Rohit
Rheumatology | November 21, 2022 | Volume: 62 | Issue: 7 | Pages: 2453-2463
Abstract Objective To determine COVID-19 vaccine-related adverse events (AEs) in the seven-day post-vaccination period in patients with SLE vs autoimmune rheumatic diseases (AIRDs), non-rheumatic autoimmune diseases (nrAIDs), and healthy controls (HC). Methods Data were captured through the COVID-19 Vaccination in Autoimmune Diseases (COVAD) questionnaire (March–December 2021). Multivariable regression models accounted for age, gender, ethnicity, vaccine type and background treatment. Results Among 9462 complete respondents, 583 (6.2%) were SLE patients (mean age: 40.1 years; 94.5% females; 40.5% Asian; 42.9% Pfizer-recipients). Minor AEs were reported by 83.0% of SLE patients, major by 2.6%, hospitalization by 0.2%. AE and hospitalization frequencies were similar between patients with active and inactive SLE. Rashes were more frequent in SLE patients vs HC (OR; 95% CI: 1.2; 1.0, 1.5), chills less frequent in SLE vs AIRDs (0.6; 0.4, 0.8) and nrAIDs (0.5; 0.3, 0.8), and fatigue less frequent in SLE vs nrAIDs (0.6; 0.4, 0.9). Pfizer-recipients reported higher overall AE (2.2; 1.1, 4.2) and injection site pain (2.9; 1.6, 5.0) frequencies than recipients of other vaccines, Oxford/AstraZeneca-recipients more body ache, fever, chills (OR: 2.5, 3.0), Moderna-recipients more body ache, fever, chills, rashes (OR: 2.6, 4.3). Hospitalization frequencies were similar across vaccine types. AE frequencies were similar across treatment groups, although chills were less frequent in antimalarial users vs non-users (0.5; 0.3, 0.9). Conclusion While COVID-19 vaccination-related AEs were reported by four-fifths of SLE patients, those were mostly minor and comparable to AEs reported by healthy individuals, providing reassurance regarding COVID-19 vaccination safety in SLE.